Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

BACKGROUND: Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more closely align with cardiovascular risk than low-density lipoprotein cholesterol (LDL-C). We describe the design and rationale of the OD...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller-Wieland, Dirk, Leiter, Lawrence A., Cariou, Bertrand, Letierce, Alexia, Colhoun, Helen M., Del Prato, Stefano, Henry, Robert R., Tinahones, Francisco J., Aurand, Lisa, Maroni, Jaman, Ray, Kausik K., Bujas-Bobanovic, Maja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445362/
https://www.ncbi.nlm.nih.gov/pubmed/28545518
http://dx.doi.org/10.1186/s12933-017-0552-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445362/
https://www.ncbi.nlm.nih.gov/pubmed/28545518
http://dx.doi.org/10.1186/s12933-017-0552-4

Ejemplares similares